- Advertisement -
- Advertisement -

Related

Norron Cheers Hansa Medical Fast Track Designation

Latest Report

- Advertisement -

Stockholm (Hedgenordic) – The share price of Swedish Hansa Medical, a biopharmaceutical company focusing on treatments for rare and severe autoimmune conditions, jumped higher Wednesday morning on the news that the U.S. Food and Drug Administration (FDA) had granted imlifidase Fast Track Designation for the investigation of imlifidase for transplantation.

Among funds having significant holdings in the company is Norron Alpha and Norron Active from Swedish hedge fund manager Norron. According to Morningstar, Hansa Medical has a portfolio weight of 4.3 percent in the two respective funds.

In a comment to the news, Gustaf Sjögren (pictured), portfolio manager at Norron says:

“The news from Hansa today, that a fast track designation has been granted by the FDA, is positive and means that they will speed up the process as the treatment is believed to be important enough. This does not mean that the probability of the treatment being approved is higher, but it is already within the 80-85 percent probability range.”

“We hope that today´s news will shorten the approval process by a number of months, meaning  that the company will have a drug ready for the market by Q4 2019.”

Hansa Medical trades 7 percent higher by midday Wednesday at SEK 330 per share, having traded as high as SEK 343 per share earlier in the session.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

HedgeNordic Editorial Team
HedgeNordic Editorial Team
This article was written, or published, by the HedgeNordic editorial team.

Latest Articles

Merger Cleared: Carlsson Norén to Transition Funds to UCITS

After nearly two decades as an independent fund manager, Carlsson Norén Asset Management is joining Meriti Capital, following regulatory approval from Finansinspektionen. Its two...

Symmetry Grows Almost Tenfold in 5 Years, Surpasses DKK 1 Billion

A disciplined investment strategy, strong performance, an expanded team, and a more institutionalized setup have helped long/short equity fund Symmetry Invest surpass DKK 1...

Norron Select’s Rocky Start and Swift Recovery

Off to a strong start in January, long/short equity fund Norron Select faced a challenging February, March, and early April, with its year-to-date performance...

Varma’s Hedge Funds Show Steady Performance

The first half of 2025 was far from smooth sailing for investors, hedge fund managers included. Varma, Finland’s largest hedge fund investor, nevertheless reported...

Proxy P Sees Signs of a Paradigm Shift

After two challenging years and a rocky start to 2025, Proxy Renewable Long/Short Energy has posted a strong three-month rally, generating a cumulative return...

Quirky Questions for Eric Strand (AuAg Funds)

Not every hedge fund conversation has to center solely on strategy, returns, or market moves. In HedgeNordic’s Quirky Questions series, we explore the minds...

Allocator Interviews

In-Depth: High Yield

Voices

Request for Proposal

- Advertisement -
HedgeNordic
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.